London: Medial journal The Lancet issued a correction on a large observational study that linked use of anti-malarial drug hydroxychloroquine with increased death risk in COVID-19 patients, after more than 100 scientists and medical professionals raised questions about integrity of data analysed in the study.
The study published on May 22 led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients.
In the correction issued on Friday, Lancet said that one hospital self-designated as belonging to the Australasia continental designation should have been assigned to the Asian continental designation.